Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 11 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Dexamethasone Tablets USP, one milligram. This medication is used to treat various medical conditions including arthritis and cancer. The tablets will be manufactured at the company's facility in Baddi, Himachal Pradesh. The press release highlights that the product had annual sales of a significant amount in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases